Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 218,237,304 papers from all fields of science
Search
Sign In
Create Free Account
Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine protocol
Known as:
C-MOPP
, CMOPP
, Cyclophosphamide/Mechlorethamine/Prednisone/Procarbazine/Vincristine
A chemotherapy combination consisting of cyclophosphamide, mechlorethamine, prednisone, procarbazine, and vincristine.
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Cyclophosphamide
Mechlorethamine hydrochloride
Prednisone
Procarbazine Hydrochloride
Expand
Narrower (1)
Procarbazine
Broader (2)
cisplatin/cyclophosphamide/etoposide protocol
cyclophosphamide/prednisone/procarbazine/vincristine protocol
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Linfoma de Hodkin en Chile: Experiencia de 15 años del Programa Nacional de Cáncer del Adulto
L. HernánGarcía
,
V. VivianLois
,
+11 authors
H. JanetRosas
2007
Corpus ID: 71539161
Median age was 37 years (15-84). Nodularsclerosis and mixed cellularity were equally expressed. Advanced stages (III & IV) were…
Expand
2000
2000
Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C‐MOPP/ABV) as first‐line treatment for patients with advanced…
S. Montoto
,
M. Camós
,
+8 authors
E. Montserrat
Cancer
2000
Corpus ID: 35794963
Combination chemotherapy, including hybrid regimens, is the standard treatment for patients with advanced Hodgkin disease (HD…
Expand
2000
2000
Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's…
T. Takenaka
,
C. Mikuni
,
+15 authors
M. Shimoyama
Japanese Journal of Clinical Oncology
2000
Corpus ID: 11388374
BACKGROUND The main form of cytotoxic treatment for advanced Hodgkin's disease (HD) is conventional dose multiagents chemotherapy…
Expand
1993
1993
C‐MOPP/ABV yields good results in a public hospital population with Hodgkin disease in Brazil
N. Spector
,
M. A. Costa
,
+10 authors
H. D. de Oliveira
Cancer
1993
Corpus ID: 31077218
Background. Over the last 15 years, a number of combination chemotherapy regimens have been reported to induce more than 80…
Expand
Highly Cited
1984
Highly Cited
1984
Prolonged initial remission in patients with nodular mixed lymphoma.
D. Longo
,
R. Young
,
+5 authors
V. Devita
Annals of Internal Medicine
1984
Corpus ID: 13538006
Seventy-nine patients with nodular mixed lymphoma were treated at the National Cancer Institute between 1966 and 1978. Fifteen…
Expand
1983
1983
Combination chemotherapy for the treatment of Hodgkin's disease in relapse
D. Straus
,
J. Myers
,
B. Koziner
,
Burton J. Lee
,
B. Clarkson
Cancer Chemotherapy and Pharmacology
1983
Corpus ID: 20503112
SummaryVindesine (desacetyl vinblastine amide sulfate, DVA) was used in combination with CCNU (lomustine) and melphalan (Alkeran…
Expand
1979
1979
A comparison between combination chemotherapy and total body irradiation plus combination chemotherapy in non‐Hodgkin's lymphoma
H. Brereton
,
R. Young
,
+5 authors
Ralph E. Johnson
Cancer
1979
Corpus ID: 45930512
Thirty‐nine untreated patients with either lymphocytic or nodular mixed/nodular histiocytic non‐Hodgkin's lymphoma, stage II‐IV…
Expand
1978
1978
The treatment of combination chemotherapy‐resistant Hodgkin disease with single‐agent vinblastine
R. Warren
,
R. Bender
,
L. Norton
,
R. Young
American journal of hematology/oncology
1978
Corpus ID: 43812055
Vinblastine has been an effective single agent for initial induction therapy of advanced Hodgkin disease. To investigate the…
Expand
Highly Cited
1977
Highly Cited
1977
Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy.
R. Fisher
,
V. Devita
,
B. Johnson
,
R. Simon
,
R. Young
American Journal of Medicine
1977
Corpus ID: 40798895
1977
1977
Successful chemotherapy of advanced non-Hodgkin's lymphoma after relapse following total body irradiation.
H. Brereton
,
R. Fairey
,
R. Johnson
International Journal of Radiation Oncology…
1977
Corpus ID: 38856713
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE